Procalcitonin can be used as a marker of premature atherosclerosis in acromegaly
详细信息 查看全文
- 作者：H. Ozkan (1)
O. Celik (1)
E. Hatipoglu (1)
F. Kantarci (2)
P. Kadioglu (1) kadioglup@yahoo.com - 关键词：Acromegaly – ; Atherosclerosis – ; Procalcitonin – ; Inflammatory markers – ; Intima media thickness
- 刊名：Pituitary
- 出版年：2012
- 出版时间：September 2012
- 年：2012
- 卷：15
- 期：3
- 页码：358-364
- 全文大小：215.3 KB
- 参考文献：1. Colao A, Baldelli R, Marzullo P et al (2000) Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 85:193–199
2. Sowers JR, Standley PR, Ram JL, Jacober S, Simpson L, Rose K (1993) Hyperinsulinemia, insulin resistance, and hyperglycemia: contributing factors in the pathogenesis of hypertension and atherosclerosis. Am J Hypertens 6:260–270
3. Courville C, Mason VR (1938) The heart in acromegaly. Arch Intern Med 61:704–713
4. Goldberg MB, Lisser H (1942) Acromegaly: a consideration of its course and treatment. Report of four cases with autopsies. J Clin Endocrinol Metab 2:477–501
5. Hejtmancik MR, Bradfield JY, Herrmann GR (1950) Acromegaly and heart: a clinical and pathologic study. Ann Intern Med 34:1445–1456
6. Lie JT, Grossman SJ (1980) Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J 100:41–52
7. Pignoli P, Tremoli E, Poli A, Paoletti R (1986) Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 74:1399–1406
8. Mukherjee D, Yadav JS (2002) Carotid artery intimal-medial thickness: indicator of atherosclerotic burden and response to risk factor modification. Am Heart J 144:753–759
9. Salonen JT, Salonen R (1993) Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 87:1156–1165
10. Colao A, Marzullo P, Lombardi G (2002) Effects of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol 146:303–309
11. Otsuki M, Kasayama S, Yamamoto H et al (2001) Characterization of premature atherosclerosis of carotid arteries in acromegalic patiens. Clin Endocrinol (Oxf) 54:791–796
12. Vitale G, Pivonello R, Lombardi G, Colao A (2004) Cardiovascular complications in acromegaly. Minerva Endocrinol 29:77–88
13. Wilson PW (1994) Established risk factors and coronary artery disease: the Framingham study. Am J Hypertens 7:7–12
14. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695
15. Ilhan F, Akbulut H, Karaca I, Godekmerdan A, Ilkay E, Bulut V (2005) Procalcitonin, C-reactive protein and neopterin levels in patients with coronary atherosclerosis. Acta Cardiol 60:361–365
16. Alexander RW (1994) Inflammation and coronary artery disease. N Engl J Med 331:468–469
17. Erren M, Reinecke H, Junker R et al (1999) Systemic inflammatory parameters in patients with atheroscleosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 19:2355–2363
18. Meisner M, Tschaikowsky K, Schnabel S, Schmidt J, Katalinic A, Sch眉ttler J (1997) Procalcitonin–influence of temperature, storage, anticoagulation and arterial or venous asservation of blood samples on procalcitonin concentrations. Eur J Chem Clin Biochem 35:597–601
19. Maruna P, Nedelnikova K, Gurlich R (2000) Physiology and genetics of procalcitonin. Physiol Res 49:57–61
20. Giustina A, Barkan A, Casanuea FF et al (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526–529
21. Bastard JP, Grimaldi A, Jardel C, Porquet D, Bruckert E, Hainque B (1997) A simple index of insulin resistance. Diabetes Metab 23:87–88
22. Cannavo S, Almoto B, Cavalli G et al (2006) Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J Clin Endocrinol Metab 91:3766–3772
23. Berg C, Petersenn S, Lahner H et al (2010) Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab 95:3648–3656
24. Bogazzi F, Battolla L, Spinelli C, Rossi G et al (2007) Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab 92:4271–4277
25. Boero L, Manavela M, G贸mez Rosso L et al (2009) Alterations in biomarkers of cardiovascular disease (CVD) in active acromegaly. Clin Endocrinol (Oxf) 70:88–95
26. Kałuzny M, Bolanowski M, Daroszewski J, Szuba A (2010) The role of fibrinogen and CRP in cardiovascular risk in patients with acromegaly. Endokrynol Pol 61:83–88
27. Potter BJ, Beauregard C, Serri O (2008) Serum markers of cardiovascular risk in patients with acromegaly before and after six months of treatment with octreotide LAR. Pituitary 11:49–53
28. Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU (2002) Cardiovascular risk factors in acromegaly before and after normalization of serum IGF–1 levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 87:1692–1699
29. Sent眉rk T, Cordan J, Baran I et al (2007) Procalcitonin in patients with acute coronary syndrome: correlation with high-sensitive C-reactive protein, prognosis and severity of coronary artery disease. Acta Cardiol 62:135–141
30. Sinning CR, Sinning JM, Schulz A et al (2011) Association of serum Procalcitonin with cardiovascular prognosis in coronary artery disease. Circ J 75(5):1184–1191
31. Colao A, Spiezia S, Pivonello R et al (2001) Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin Endocrinol (Oxf) 54:515–524
32. Kartal I, Oflaz H, Pamuk莽u B et al (2010) Investigation of early atherosclerotic changes in acromegalic patients. Int J Clin Pract 64:39–44
33. Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS (1994) Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int 45:598–604
34. B枚ger RH, Bode-B枚ger SM, M眉gge A et al (1995) Supplementation of hypercholesterolaemic rabbits with l-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis 117:273–284
35. Tsao PS, Theilmeier G, Singer AH, Leung LL, Cooke JP (1994) l-arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscler Thromb 14:1529–1533
36. Sakai H, Tsuchiya K, Nakayama C et al (2008) Improvement of endothelial dysfunction in acromegaly after transsphenoidal surgery. Endocr J 55:853–859
37. Herrmann BL, Severing M, Schmermund A et al (2009) Impact of disease duration on coronary calcification in patients with acromegaly. Exp Clin Endocrinol Diabetes 117:417–422 - 作者单位：1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Cerrahpasa Medical School, University of Istanbul, Cerrahpasa Tip Fak眉ltesi, Ic Hastal谋klar谋 Anabilim Dali, Endokrinoloji-Metabolizma ve Diyabet Bilim Dali, Cerrahpasa, 34303 Istanbul, Turkey2. Department of Radiology, Cerrahpasa Medical School, University of Istanbul, Istanbul, Turkey
- ISSN：1573-7403
文摘
The objective of the study was to evaluate arterial morphologic changes of early atherosclerosis and changes in procalcitonin (PCT) levels in patients with acromegaly according to disease activity. Thirty-three active and 20 inactive acromegaly patients followed at Endocrinology-Metabolism out-patient clinic of Cerrahpasa Medical Faculty between 2004 and 2008 were included in the study. Twenty gender and age matched healthy subjects were included as the control group. Intima-media thickness (IMT) of the carotid arteries was measured by ultrasonography. Blood was drawn for biochemical tests and the serum concentrations of C-reactive protein (CRP) and PCT. Intergroup analysis revealed no significant differences between Growth hormone (GH), insulin like growth factor-1 (IGF-1), and IMT (P = 0.42, P = 0.47 respectively). No significant differences were found in the fibrinogen, CRP and PCT levels of the acromegaly patients and the subjects in the control group (P = 0.57, P = 0.84, P = 0.68 respectively). In the patients with IMT ≥ 1 mm, PCT (0.4 [IQR: 0.4–0.55]) levels were significantly different from the patients without atherosclerosis (0.06 [IQR: 0.05–0.12], P < 0.001). The correlation between IMT and PCT (P = 0.001, r = 0.47) was more significant than the correlation between IMT and CRP (P = 0.01, r = 0.28). There was a positive correlation between IMT and atherosclerotic risk factors such as age (P = 0.01, r = 0.27) and body mass index (BMI; P = 0.005, r = 0.32). Our results showed that PCT increases before CRP and it can be useful for the assessment of premature atherosclerosis in acromegaly as well.